Hyundai Pharmaceutical Co., Ltd. (KRX:004310)
South Korea · Delayed Price · Currency is KRW 12,680
-430 (-3.28%)
Feb 26, 2026, 11:10 AM KST
Hyundai Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is December - November.
Millions KRW. Fiscal year is Dec - Nov.
Fiscal Year | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 |
|---|---|---|---|---|---|
Period Ending | Nov '13 Nov 30, 2013 | Nov '12 Nov 30, 2012 | Nov '11 Nov 30, 2011 | Nov '10 Nov 30, 2010 | Nov '09 Nov 30, 2009 |
Operating Revenue | 108,135 | 102,253 | 114,276 | 111,860 | 122,879 |
Other Revenue | 0 | -0 | - | - | - |
| 108,135 | 102,253 | 114,276 | 111,860 | 122,879 | |
Revenue Growth (YoY) | 5.75% | -10.52% | 2.16% | -8.97% | 1.96% |
Cost of Revenue | 67,644 | 63,183 | 68,592 | 66,331 | 73,697 |
Gross Profit | 40,491 | 39,071 | 45,684 | 45,529 | 49,182 |
Selling, General & Admin | 37,360 | 41,997 | 41,076 | 44,417 | 44,588 |
Research & Development | 67.69 | 391.59 | 165.4 | 659.63 | 1,813 |
Amortization of Goodwill & Intangibles | 114.56 | 158.47 | 163.6 | 208.66 | 229.58 |
Other Operating Expenses | 452.61 | 325.58 | 374.22 | 561.25 | 598.7 |
Operating Expenses | 38,304 | 43,390 | 42,223 | 46,412 | 48,012 |
Operating Income | 2,187 | -4,319 | 3,460 | -882.8 | 1,171 |
Interest Expense | -973.72 | -1,269 | -1,355 | -1,273 | -1,213 |
Interest & Investment Income | 517.65 | 527.68 | 386.47 | 560.86 | 703.49 |
Earnings From Equity Investments | - | - | - | 146.24 | -9.29 |
Currency Exchange Gain (Loss) | 160 | 141.22 | 122.07 | 147.19 | 1,519 |
Other Non Operating Income (Expenses) | -1,081 | -1,065 | -742.52 | -41.63 | -477.09 |
EBT Excluding Unusual Items | 810.3 | -5,983 | 1,871 | -1,343 | 1,694 |
Gain (Loss) on Sale of Investments | - | 2.83 | 14.9 | - | 487.31 |
Gain (Loss) on Sale of Assets | 340.5 | -233.65 | -92.68 | 5,137 | -262.18 |
Pretax Income | 1,151 | -6,214 | 1,793 | 3,794 | 1,919 |
Income Tax Expense | -308.81 | -1,366 | 1,250 | 825.86 | 248.73 |
Earnings From Continuing Operations | 1,460 | -4,848 | 542.94 | 2,968 | 1,671 |
Minority Interest in Earnings | -44.73 | -2.16 | -22.84 | - | - |
Net Income | 1,415 | -4,850 | 520.1 | 2,968 | 1,671 |
Net Income to Common | 1,415 | -4,850 | 520.1 | 2,968 | 1,671 |
Net Income Growth | - | - | -82.48% | 77.67% | -51.93% |
Shares Outstanding (Basic) | 23 | 23 | 24 | 24 | 25 |
Shares Outstanding (Diluted) | 23 | 23 | 24 | 24 | 25 |
Shares Change (YoY) | 0.08% | -0.90% | -0.97% | -2.94% | -7.44% |
EPS (Basic) | 60.34 | -207.00 | 22.00 | 124.33 | 67.93 |
EPS (Diluted) | 60.34 | -207.00 | 22.00 | 124.33 | 67.93 |
EPS Growth | - | - | -82.31% | 83.05% | -48.07% |
Free Cash Flow | 5,710 | -4,154 | 2,586 | -1,267 | -9,216 |
Free Cash Flow Per Share | 243.49 | -177.31 | 109.37 | -53.09 | -374.72 |
Dividend Per Share | - | - | - | 45.000 | 50.000 |
Dividend Growth | - | - | - | -10.00% | -23.08% |
Gross Margin | 37.45% | 38.21% | 39.98% | 40.70% | 40.02% |
Operating Margin | 2.02% | -4.22% | 3.03% | -0.79% | 0.95% |
Profit Margin | 1.31% | -4.74% | 0.46% | 2.65% | 1.36% |
Free Cash Flow Margin | 5.28% | -4.06% | 2.26% | -1.13% | -7.50% |
EBITDA | 4,298 | -1,962 | 5,930 | 1,406 | 3,775 |
EBITDA Margin | 3.97% | -1.92% | 5.19% | 1.26% | 3.07% |
D&A For EBITDA | 2,111 | 2,357 | 2,470 | 2,289 | 2,605 |
EBIT | 2,187 | -4,319 | 3,460 | -882.8 | 1,171 |
EBIT Margin | 2.02% | -4.22% | 3.03% | -0.79% | 0.95% |
Effective Tax Rate | - | - | 69.73% | 21.77% | 12.96% |
Revenue as Reported | - | - | - | 111,860 | 122,879 |
Advertising Expenses | 7,205 | 7,858 | 7,673 | 11,086 | 12,080 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.